90-Days mortality rate in patients treated within the context of a phase-I trial: How should we identify patients who should not go on trial?

There is good evidence that our easily derivable scoring system provides an objective method to identify patients with a very limited life expectancy in whom participation in phase-I trials should be carefully evaluated.